For the first time, the company introduced Zhang Qiang, a national leader, as the chief scientist of Jianfeng Pharmaceutical.


Release time:

2022-07-27

In early July, Dr. Zhang Qiang, a national leader and former researcher at the Karolinska Institute in Sweden, officially joined the peak as the chief scientist of peak pharmaceutical. This is the first time that Jianfeng has introduced national leading talents, and it is also the first time that Wucheng District has introduced national leading talents by enterprises.

    7At the beginning of the month, Dr. Zhang Qiang, a national leader and former researcher at the Karolinska Institute in Sweden, officially joined the peak as the chief scientist of the peak pharmaceutical industry. This is the first time that Jianfeng has introduced national leading talents, and it is also the first time that Wucheng District has introduced national leading talents by enterprises.

    National leading talents, that is, selected countriesThe "tens of millions of talents project" can focus on the national development strategic objectives, in various parks such as national key innovation projects, key disciplines and key laboratories, central enterprises and state-owned commercial and financial institutions, and high-tech industrial development zones, etc., To achieve strategic scientists and leading talents who break through key technologies, develop high-tech industries, and drive emerging disciplines. The company introduced Dr. Zhang Qiang,1981Born in, after completing bachelor's and master's studies at Jilin Agricultural University and Beijing Jiaotong University, he studied for a doctorate in life sciences at the Karolinska Institute in Sweden, which ranks fifth in the world for medical majors. After graduation, he conducted postdoctoral research in the institute. Serving as a researcher. Dr. Zhang Qiang's research in cell culture, cell transfection, cell proliferation assay, pharmaceutical pharmacology, protein structure simulation, structure-activity relationship(SAR)He has more than ten years of experience in the research and development of small molecule anti-tumor drugs, and has rich experience in drug screening and development. After joining Jianfeng Pharmaceutical, he will use his technical expertise to be responsible for the establishment of drug screening platforms and research on drug mechanisms, cell testing, and pharmacology research.

    Continuously introducing high-end talents and optimizing the peak talent structure has always been the direction of the company's talent strategy. Xiang Chongping, deputy general manager of the group company, said that the introduction of national leading talents is an important achievement of the company's human resources work. Taking this as an opportunity, the company will further strengthen the introduction of talents, continuously optimize the talent management and use mechanism, and give foreign talents the space and stage to fully display their talents, so as to attract more high-end talents to join the peak; at the same time, it will also strengthen the training of internal talents, promote their faster growth, promote the continuous optimization of the company's talent team, and provide greater impetus for the innovation and development of enterprises.